---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000130"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:07:29.140438+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical regains Nasdaq compliance, avoids delisting

## Summary
- Filed overdue Q3 FY2023 and Q1/Q2 FY2024 10-Qs on Aug 8, 2024, and FY2024 10-K on Aug 26, 2024.
- Held 2024 annual meeting on Aug 15, 2024, curing Annual Meeting Rule deficiency.
- Nasdaq will monitor compliance until Sept 4, 2025; further failure to file timely could lead to delisting without cure period.
- Company's common stock remains listed on The Nasdaq Global Select Market.

## SEC filing metadata
- accession: 0001005286-24-000130
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000130/0001005286-24-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000130/lndc-20240911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000130
- JSON: https://secwatch.observer/filing/0001005286-24-000130.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.